Actualités

The newly issued publication ‘Basic Recommendations in Brief for Treating Physicians’, based on and complementing the ‘Guidelines for the Management of Transfusion Dependent Thalassaemia (4th Edition – 2021)’, is an…

Every single one of us has the ability to make a difference, large or small, and together we can make real progress in raising valuable awareness about thalassaemia and its…

The objective of this meeting, which brings together eminent haemoglobinopathies specialists and expert patient advocates from Italy and other countries, is to highlight the pivotal value of advocacy in enabling…

Rosario was more than eager to recount this wonderful experience to TIF for the International Thalassaemia Day 2022 and share some inspiring messages with his peers. “It is important to…

Visit the International Thalassaemia Day (ITD) 2022 page, now LIVE on the TIF website, to discover the idea behind the  »Be Aware. Share. Care. » theme, our fantastic campaign resources, the…

Rare Disease Day is the movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease everywhere…

The US Food and Drug Administration (FDA) has announced the approval of Mitapivat (PYRUKYND®) tablets as treatment for haemolytic anemia in adults with pyruvate kinase (PK) deficiency. The oral PK…

Many pharmaceutical companies are making remarkable progress in their research into candidate treatments for these diseases and 2022 is expected to be yet another eventful year for haemoglobin disorders! Check…

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for Oxbryta® (voxelotor) tablets for the treatment of hemolytic…